Claus A. Hanusch
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2026
Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.
Journal: Breast (Edinburgh, Scotland)
Published: January 05, 2026
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.
Journal: NPJ breast cancer
Published: January 04, 2026
Optimization of Ki67 digital image analysis in breast cancer by automated tumor area identification.
Optimization of Ki67 digital image analysis in breast cancer by automated tumor area identification.
Journal: Virchows Archiv : an international journal of pathology
Published: October 16, 2025
Correction: Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer.
Journal: Breast cancer research and treatment
Published: June 19, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).
Journal: ESMO open
Published: June 18, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
Journal: The Lancet. Oncology
Published: March 13, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 30, 2025
Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer.
Journal: Breast cancer research and treatment
Published: November 01, 2024
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 27, 2024
Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Journal: Clinical and translational medicine
Published: November 08, 2023
Last Updated: 09/26/2026